Zymeworks Inc (ZYME) NPV

Sell:$12.57Buy:$12.58$0.04 (0.32%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$12.57
Buy:$12.58
Change:$0.04 (0.32%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$12.57
Buy:$12.58
Change:$0.04 (0.32%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Key people

Kenneth H. Galbraith
Chairman of the Board, President, Chief Executive Officer
Leone D. Patterson
Chief Financial Officer, Chief Business Officer, Executive Vice President
Jeffrey Smith
Executive Vice President and Chief Medical Officer
Paul A. Moore
Chief Scientific Officer
Susan M. Mahony
Lead Independent Director
Oleg Nodelman
Director
Carlos E. Campoy
Independent Director
Alessandra Cesano
Independent Director
Troy M. Cox
Independent Director
Click to see more

Key facts

  • EPIC
    ZYME
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US98985Y1082
  • Market cap
    $866.23m
  • Employees
    280
  • Shares in issue
    69.58m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.